34 research outputs found
Diatomite alleviates the adverse effects of salinity stress on growth and yield of Stevia rebaudiana
ABSTRACT The present study was planned to investigate the role of diatomitein salt tolerance of Stevia rebaudiana using pot experimental. Diatomite increased the growth characters of plants, hence resulted in higher yields. In contrast, the seawater treatments alone significantly decreased these parameters in both seasons. While, treating Stevia rebaudianaplants with diatomite prior to salinity stress decreased the detrimental effectof salt stress on growth and yield.The Esterase isoenzymesprofiles has indicated that salinity, diatomite and their combinations has caused biochemical changes in Steviar. plants. On the other hand, saline water irrigation decreased Rebaudioside A concentration at the second harvest as estimated by HPLC analysis in both seasons .The effect of the interaction between salinity and diatomite was the mosteffective treatments for Rebaudioside A when Stevia rebaudianaplants treated by salt concentration 4000 ppm and 2.5 g/kgsoil diatomite
HYPOGLYCEMIC EFFECT OF LUPIN ALKALOIDS AND/OR ROSIGLITAZONE IN PREGNANT DIABETIC RATS IN RELATION TO ATHEROGENIC INDEX
Diabetes (DM) is a group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion and/ or insulin action. It can be classified into; type 1 (T1DM) Type 2 DM, type 2 (T2DM), gestational diabetes and other specific types of diabetes. Diabetes is the most common pre-existing medical condition complicating pregnancy. Insulin resistance is associated with both type two diabetes and dislypedemia. This study aims to evaluate the changes in the homeostasis model assessment of insulin resistance (HOMA- IR) and indices of atherogenic lipid profile parameters in pregnant diabetic rats after the administration of Rosiglitazone and /or alkaloid lupine extract. Blood glucose, hemoglobin content (Hb), lipid profile, insulin and glucagon concentrations were investigated at 20th day of gestation. The results revealed the improvement of HOMA-IR and The control of the hyperglycemic status in all treated group. Also, there are an increase in insulin concentration, and a decrease in glucagon concentration in all treated groups, in comparison to, STZ group. Meanwhile, it showed alternation in the atherogenic profile in Rosiglitazone treated groups, in comparison to, lupin treated groups. The correlations among (HOMA-IR and HDL), (AIP and LDL) and (glucose and Hb) were observed in our study at (r = 0.594, p< 0.01), (r = 0.690, p< 0.01), and (r = 0.811, p< 0.01) respectively. The usage of lupine alkaloids to treating type two diabetes during the pregnancy is more favorable to avoid Rosiglitazone side effects. More studies are needed to explore the effect of Rosiglitazone on lipids and cardiovascular risk
Surveillance on A/H5N1 virus in domestic poultry and wild birds in Egypt
The endemic H5N1 high pathogenicity avian influenza virus (A/H5N1) in poultry
in Egypt continues to cause heavy losses in poultry and poses a significant
threat to human health. Here we describe results of A/H5N1 surveillance in
domestic poultry in 2009 and wild birds in 2009-2010. Tracheal and cloacal
swabs were collected from domestic poultry from 22024 commercial farms, 1435
backyards and 944 live bird markets (LBMs) as well as from 1297 wild birds
representing 28 different types of migratory birds. Viral RNA was extracted
from a mix of tracheal and cloacal swabs media. Matrix gene of avian influenza
type A virus was detected using specific real-time reverse-transcription
polymerase chain reaction (RT-qPCR) and positive samples were tested by RT-
qPCR for simultaneous detection of the H5 and N1 genes. In this surveillance,
A/H5N1 was detected from 0.1% (n = 23/) of examined commercial poultry farms,
10.5% (n = 151) of backyard birds and 11.4% (n = 108) of LBMs but no wild bird
tested positive for A/H5N1. The virus was detected from domestic poultry year-
round with higher incidence in the warmer months of summer and spring
particularly in backyard birds. Outbreaks were recorded mostly in Lower Egypt
where 95.7% (n = 22), 68.9% (n = 104) and 52.8% (n = 57) of positive
commercial farms, backyards and LBMs were detected, respectively. Higher
prevalence (56%, n = 85) was reported in backyards that had mixed chickens and
waterfowl together in the same vicinity and LBMs that had waterfowl (76%, n =
82). Our findings indicated broad circulation of the endemic A/H5N1 among
poultry in 2009 in Egypt. In addition, the epidemiology of A/H5N1 has changed
over time with outbreaks occurring in the warmer months of the year. Backyard
waterfowl may play a role as a reservoir and/or source of A/H5N1 particularly
in LBMs. The virus has been established in poultry in the Nile Delta where
major metropolitan areas, dense human population and poultry stocks are
concentrated. Continuous surveillance, tracing the source of live birds in the
markets and integration of multifaceted strategies and global collaboration
are needed to control the spread of the virus in Egypt
Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus
In Egypt, ducks kept for commercial purposes constitute the second highest poultry population,
at 150 million ducks/year. Hence, ducks play an important role in the introduction and
transmission of avian influenza (AI) in the Egyptian poultry population. Attempts to control
outbreaks include the use of vaccines, which have varying levels of efficacy and failure. To
date, the effects of vaccine efficacy has rarely been determined in ducks. In this study, we
evaluated the protective efficacy of a live recombinant vector vaccine based on a turkey
Herpes Virus (HVT) expressing the H5 gene from a clade 2.2 H5N1 HPAIV strain (A/Swan/
Hungary/499/2006) (rHVT-H5) and a bivalent inactivated H5N1 vaccine prepared from
clade 2.2.1 and 2.2.1.1 H5N1 seeds in Mulard ducks. A 0.3ml/dose subcutaneous injection
of rHVT-H5 vaccine was administered to one-day-old ducklings (D1) and another 0.5ml/
dose subcutaneous injection of the inactivated MEFLUVAC was administered at 7 days
(D7). Four separate challenge experiments were conducted at Days 21, 28, 35 and 42, in
which all the vaccinated ducks were challenged with 106EID50/duck of H5N1 HPAI virus (A/
chicken/Egypt/128s/2012(H5N1) (clade 2.2.1) via intranasal inoculation. Maternal-derived
antibody regression and post-vaccination antibody immune responses were monitored
weekly. Ducks vaccinated at 21, 28, 35 and 42 days with the rHVT-H5 and MEFLUVAC vaccines
were protected against mortality (80%, 80%, 90% and 90%) and (50%, 70%, 80%
and 90%) respectively, against challenges with the H5N1 HPAI virus. The amount of viral
shedding and shedding rates were lower in the rHVT-H5 vaccine groups than in the MEFLUVAC groups only in the first two challenge experiments. However, the non-vaccinated
groups shed significantly more of the virus than the vaccinated groups. Both rHVT-H5
and MEFLUVAC provide early protection, and rHVT-H5 vaccine in particular provides protection
against HPAI challenge.S1 Table. Weekly mean HI titres (log2 ± SD) using A/Swan/Hungary/4999/2006) rHVT/Ag
that indicate the immune response to the rHVT-H5 vaccination. S1 Table legend: Different
upper case letters in a row denote the presence of statistically significant (p 0.05) differences.
Group I (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with inactivated
KV-H5 vaccine at 8 days old), Group III (unvaccinated control).S2 Table. Weekly mean HI titres (log2 ± SD) measured using (A/chicken/Egypt/Q1995D/
2010) V/H5N1/Ag that indicates the immune response to the KV-H5 vaccination. S2
Table legend: Different upper case letters in a row denote the presence of statistically significant
(p 0.05) differences. Group 1 (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with inactivated KV-H5 vaccine at 8 days old), Group III (unvaccinated control).S3 Table. Weekly mean HI titres (log2 ± SD) measured using (A/chicken/Egypt/128S/2012)
C/H5N1/Ag that indicates the immune response to the challenge virus. S3 Table legend: Different
upper case letters in a row denote the presence of statistically significant (p 0.05) differences.
Group 1 (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with
inactivated KV-H5 vaccine at 8 days old), Group III (unvaccinated control).This work was supported by the United
States Agency for International Development
(USAID) under a grant (AID-263-IO-11-00001, Mod.
#3) and within the framework of OSRO/EGY/101/
USA, which applies to projects jointly implemented by
the FAO, GOVS and NLQP.http://www.plosone.orgam2016Production Animal StudiesVeterinary Tropical Disease
Protective efficacy of recombinant turkey herpes virus (rHVT-H5) and inactivated H5N1 vaccines in commercial Mulard ducks against the highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1 virus
In Egypt, ducks kept for commercial purposes constitute the second highest poultry population,
at 150 million ducks/year. Hence, ducks play an important role in the introduction and
transmission of avian influenza (AI) in the Egyptian poultry population. Attempts to control
outbreaks include the use of vaccines, which have varying levels of efficacy and failure. To
date, the effects of vaccine efficacy has rarely been determined in ducks. In this study, we
evaluated the protective efficacy of a live recombinant vector vaccine based on a turkey
Herpes Virus (HVT) expressing the H5 gene from a clade 2.2 H5N1 HPAIV strain (A/Swan/
Hungary/499/2006) (rHVT-H5) and a bivalent inactivated H5N1 vaccine prepared from
clade 2.2.1 and 2.2.1.1 H5N1 seeds in Mulard ducks. A 0.3ml/dose subcutaneous injection
of rHVT-H5 vaccine was administered to one-day-old ducklings (D1) and another 0.5ml/
dose subcutaneous injection of the inactivated MEFLUVAC was administered at 7 days
(D7). Four separate challenge experiments were conducted at Days 21, 28, 35 and 42, in
which all the vaccinated ducks were challenged with 106EID50/duck of H5N1 HPAI virus (A/
chicken/Egypt/128s/2012(H5N1) (clade 2.2.1) via intranasal inoculation. Maternal-derived
antibody regression and post-vaccination antibody immune responses were monitored
weekly. Ducks vaccinated at 21, 28, 35 and 42 days with the rHVT-H5 and MEFLUVAC vaccines
were protected against mortality (80%, 80%, 90% and 90%) and (50%, 70%, 80%
and 90%) respectively, against challenges with the H5N1 HPAI virus. The amount of viral
shedding and shedding rates were lower in the rHVT-H5 vaccine groups than in the MEFLUVAC groups only in the first two challenge experiments. However, the non-vaccinated
groups shed significantly more of the virus than the vaccinated groups. Both rHVT-H5
and MEFLUVAC provide early protection, and rHVT-H5 vaccine in particular provides protection
against HPAI challenge.S1 Table. Weekly mean HI titres (log2 ± SD) using A/Swan/Hungary/4999/2006) rHVT/Ag
that indicate the immune response to the rHVT-H5 vaccination. S1 Table legend: Different
upper case letters in a row denote the presence of statistically significant (p 0.05) differences.
Group I (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with inactivated
KV-H5 vaccine at 8 days old), Group III (unvaccinated control).S2 Table. Weekly mean HI titres (log2 ± SD) measured using (A/chicken/Egypt/Q1995D/
2010) V/H5N1/Ag that indicates the immune response to the KV-H5 vaccination. S2
Table legend: Different upper case letters in a row denote the presence of statistically significant
(p 0.05) differences. Group 1 (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with inactivated KV-H5 vaccine at 8 days old), Group III (unvaccinated control).S3 Table. Weekly mean HI titres (log2 ± SD) measured using (A/chicken/Egypt/128S/2012)
C/H5N1/Ag that indicates the immune response to the challenge virus. S3 Table legend: Different
upper case letters in a row denote the presence of statistically significant (p 0.05) differences.
Group 1 (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with
inactivated KV-H5 vaccine at 8 days old), Group III (unvaccinated control).This work was supported by the United
States Agency for International Development
(USAID) under a grant (AID-263-IO-11-00001, Mod.
#3) and within the framework of OSRO/EGY/101/
USA, which applies to projects jointly implemented by
the FAO, GOVS and NLQP.http://www.plosone.orgam2016Production Animal StudiesVeterinary Tropical Disease
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017 : A systematic analysis for the global burden of disease study
Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-Adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care. © 2019 American Medical Association. All rights reserved.Peer reviewe
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Structures planaires pour des applications de filtrage (structures à défauts de plan de masse, lignes à ondes lentes)
L objectif de ce travail est d étudier des configurations de structures à ondes lentes afin de présenter des applications de filtrage à la fois miniatures et performants. L étude est basée sur deux axes principaux: structures à défauts de plan de masse et lignes de transmission périodiquement chargées. Une topologie de filtre passe bande et deux topologies de filtre passe bas ont été proposées suite à la modélisation d une cellule DGS de type dumbbell modifié. Une nouvelle topologie de lignes à ondes lentes différentielles intégrées sur silicium a été également caractérisée. L effet d onde lente se manifeste dans ces lignes grâce à un bouclier de barreaux flottants en dessous de la ligne. Un facteur d onde lente de l ordre de 9 a été mesuré pour une ligne de 45 d impédance caractéristique. Cette même ligne a été utilisée comme ligne d alimentation dans un filtre ultra-large-bande sur silicium et également comme résonateur dans des filtres passe bas en technologie PCB avancée.The aim of this work is to study the different configurations of slow-wave structures in order to provide reduced size filtering applications with improved performances. This study is based on two main axes : defected ground structures and periodically loaded transmission lines. A library of transmission line models for a DGS unit cell consisting of a modified dumbbell shape has been proposed and used in the design of a bandpass filter and two lowpass filters. A new topology of slow-wave differential silicon based transmission lines has been characterised. The slow-wave effect was guaranteed thanks to a shielding grid of floating strips placed underneath the line. The measured slow-wave factor is in the order of 9 for a shielded line with 45 characteristic impedance. This transmission line has been used afterwards as a feedline for an ultra-wide bandpass filter implemented in standard 0.35 m CMOS technology and as a stub resonator for lowpass filters in advanced PCB technology.GRENOBLE1-BU Sciences (384212103) / SudocSudocFranceF
Additional file 2 of Genotyping and pathogenicity of fowl adenovirus isolated from broiler chickens in Egypt
Additional file 2: Supplementary Table 1. Representing the history of suspected sample infected, farmflocks, with FAdV (IBH) including strain used in the pathogenicity study